Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 24Neoplasm Metastasis 7Neoplasms 5Prostate Cancer Metastatic 4Carcinoma, Transitional Cell 4Recurrence 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Solid Cancer 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplastic Cells, Circulating 1Metastatic Castration-resistant Prostate Cancer 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Liposarcoma 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Breast Neoplasms 1Bone Metastatic Prostate Cancer 1Advanced Solid Tumor 1

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Everolimus 1Denosumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hormone Refractory Prostate Cancer × cabazitaxel × Clear all
NCT01518283 2017-07-02

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Spanish Oncology Genito-Urinary Group

Phase 2 Completed
74 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡